MEDBOX | Toolbox Vaxzevria (Astra Zeneca)

TOOLBOX

Advanced search

Create your MEDBOX

TOOLBOX

Advanced search

Create your MEDBOX

LIST OPTIONS

FILTER BY LANGUAGE

FILTER BY COUNTRY

SORT BY

RESULTS/PAGE

LIST TYPE

26 records

	Beschluss der STIKO zur 19. Aktualisierung der COVID-19-Impfempfehlung und die dazugehörige wissenschaftliche Begründung Vygen-Bonnet S, Koch J, Bogdan C, et al. (2022) C1 View PDF(138) Download (88) Add to my MEDBOX Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfempfehlung ist es, Personen, die eine COVID-19-Impfung mit einem der nicht in der EU zugelassenen Ganzvirusimpfstoffen (CoronaVac, Covilo und Covaxin) oder dem Vektor-basierten Impfstoff Sputnik V erhalten haben, mit einem Impfschutz auszustatten, der vergleichbar mit dem einer Grundimmunisierung plus Auffrischimpfung mit einem mRNA-Impfstoff ist Tags: Impfungen, COVID-19, Strategie, Verteilung, Ethik, Risikogruppen, Priorisierung, Deutschland, mRNA, vector-basierter Impfstoff, Astra Zeneca, Moderna, pfizer, Risiko, Sinusvenenthrombosen, Zweitimpfung, johnson&Johnson, pediatrics, Children, Adolescents, booster, Source: https://www.rki.de/DE/Content/Infekt/Epi
	Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) World Health Organization WHO (2022) C_WHO View PDF(84) Download (47) Add to my MEDBOX These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below. This document has been updated: Version 15 March 2022 Tags: Astra Zeneca, vaccine, vaccine candidates, COVID-19, Source: https://apps.who.int/iris/rest/bitstream
	Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca Medicines and Healthcare products Regulatory Agency (MHRA) UK (2021) CC View PDF(75) Download (53) Add to my MEDBOX REG 174 INFORMATION FOR UK HEALTHCARE PROFESSIONALS Tags: UK, vaccine, Astra Zeneca, regulation, COVID-19, Source: https://assets.publishing.service.gov.uk
	Предварительные рекомендации по применению вакцины ChAdOx1-S [‎рекомбинантной]‎ против COVID-19 (‎вакцина AstraZeneca COVID-19 AZD1222, Vaxzevria™, SII COVISHIELD™) World Health Organization WHO (2021) C_WHO View PDF(46) Download (26) Add to my MEDBOX временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021�� Tags: Astra Zeneca, vaccine, vaccine candidates, COVID-19, Source: https://apps.who.int/iris/bitstream/hand
	AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine World Health Organization WHO (2021) C_WHO View PDF(58) Download (37) Add to my MEDBOX 10 May 2021. Manufactureres: SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])] Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)] The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vector vaccine against coronavirus disease 2019 (COVID-19). The vaccine expresses the SARS-CoV-2 spike protein gene, which instructs the host cells to produce the protein of the S-antigen unique to SARS-CoV-2, allowing the body to generate an immune response and to retain that information in memory immune cells. Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) irrespective of interval between the doses was 63.1%, based on a median follow-up of 80 days, but tended to be higher when this interval was longer. The data reviewed at this time support the conclusion that the known and potential benefits of ChAdOx1-S/nCoV-19 [recombinant] vaccine outweigh the known and potential risks Tags: Astra Zeneca, vaccine, vaccine candidates, side effects, clinical trials, COVID-19, SARS-CoV-2, Source: https://www.who.int/docs/default-source/
	AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets European Medicines Agency EMA (2021) CC Open external link (608) Add to my MEDBOX 7 April 2021 Tags: Astra Zeneca, side effects, blood clots, vaccine, COVID-19, Source: https://www.ema.europa.eu/en/news/astraz
	Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Greinacher, A., et al. (2021) CC Open external link (535) Add to my MEDBOX New England Journal of Medicine April 9, 2021 DOI: 10.1056/NEJMoa2104840 Tags: Astra Zeneca, side effects, thrombocytopenic disorder, covid-19, Vaccination, Source: https://www.nejm.org/doi/full/10.1056/NE
	Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine World Health Organization WHO (2021) C_WHO Open external link (459) Add to my MEDBOX 7 April 2021 Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Available in Englisch, French and Russia Tags: blood clots, Astra Zeneca, side effects, Vaccination, covid-19, thrombocytopenic disorder, Source: https://www.who.int/news/item/07-04-2021
	Aktualisierte Stellungnahme der GTH zur Impfung mit dem AstraZeneca COVID-19 Vakzin, Stand 1. April 2021 Gesellschaft für Thrombose-undHämostaseforschung e.V. GTH (2021) CC View PDF(59) Download (33) Add to my MEDBOX Tags: Astra Zeneca, Risiko, impfempfehlungen, Sinusvenenthrombosen, Source: https://gth-online.org/wp-content/upload
	Job aid for COVID-19 vaccine administration: AZD1222 (‎ChAdOx1-S [‎recombinant]‎)‎ COVID-19 vaccine World Health Organization WHO, Regional Office of Europe (2021) C_WHO View PDF(43) Download (27) Add to my MEDBOX Tags: Moderna, Vaccination, COVID-19, Source: https://extranet.who.int/iris/restricted

26 records

26 records